PDCD1 and non-small cell lung carcinoma: In this pilot study (n = 21), two preoperative doses of the PD-1 inhibitor nivolumab were administered in adults with untreated, surgically resectable, early-stage (I, II, or IIIA) NSCLC, demonstrating no delays in surgery.